Halofuginone hydrobromide is primarily used in veterinary medicine as an antiprotozoal agent. It is effective in treating coccidiosis, a parasitic disease affecting the intestinal tracts of animals, particularly poultry and livestock. By inhibiting the growth and reproduction of coccidia, it helps maintain animal health and productivity. Additionally, it has shown potential in inhibiting fibrosis in various tissues, making it a subject of research in human medicine for conditions like scleroderma and cancer-related fibrosis. Its ability to modulate immune responses and collagen synthesis has also led to investigations in treating autoimmune diseases and promoting wound healing.